Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FBIO NASDAQ:MEIP NASDAQ:NATR NASDAQ:OVID NASDAQ:SPRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFBIOFortress Biotech$2.77+0.4%$2.50$1.70▼$4.53$92.02M1.22465,429 shs284,942 shsMEIPMEI Pharma$3.19+14.7%$3.98$1.92▼$9.00$104.72M0.38919,067 shs3.98 million shsNATRNature's Sunshine Products$20.51+0.5%$23.76$12.97▼$28.14$358.73M0.86137,280 shs123,608 shsOVIDOvid Therapeutics$2.30+4.1%$2.60$0.27▼$3.11$412.48M0.161.42 million shs2.06 million shsSPROSpero Therapeutics$2.85+5.6%$2.69$1.80▼$3.22$156.33M1.45820,654 shs623,665 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFBIOFortress Biotech+0.36%+4.53%+24.22%-10.65%+31.90%MEIPMEI Pharma0.00%0.00%0.00%0.00%+36.87%NATRNature's Sunshine Products+0.54%+3.64%-8.15%-16.25%+44.23%OVIDOvid Therapeutics+4.07%-4.17%-17.86%+16.75%+621.46%SPROSpero Therapeutics+5.56%+1.06%+16.80%+10.47%+1.79%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFBIOFortress Biotech$2.77+0.4%$2.50$1.70▼$4.53$92.02M1.22465,429 shs284,942 shsMEIPMEI Pharma$3.19+14.7%$3.98$1.92▼$9.00$104.72M0.38919,067 shs3.98 million shsNATRNature's Sunshine Products$20.51+0.5%$23.76$12.97▼$28.14$358.73M0.86137,280 shs123,608 shsOVIDOvid Therapeutics$2.30+4.1%$2.60$0.27▼$3.11$412.48M0.161.42 million shs2.06 million shsSPROSpero Therapeutics$2.85+5.6%$2.69$1.80▼$3.22$156.33M1.45820,654 shs623,665 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFBIOFortress Biotech+0.36%+4.53%+24.22%-10.65%+31.90%MEIPMEI Pharma0.00%0.00%0.00%0.00%+36.87%NATRNature's Sunshine Products+0.54%+3.64%-8.15%-16.25%+44.23%OVIDOvid Therapeutics+4.07%-4.17%-17.86%+16.75%+621.46%SPROSpero Therapeutics+5.56%+1.06%+16.80%+10.47%+1.79%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFBIOFortress Biotech 2.25Hold$17.00513.72% UpsideMEIPMEI Pharma 0.00N/AN/AN/ANATRNature's Sunshine Products 2.67Moderate Buy$35.0070.65% UpsideOVIDOvid Therapeutics 2.89Moderate Buy$5.13122.83% UpsideSPROSpero Therapeutics 1.50ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest FBIO, NATR, MEIP, SPRO, and OVID Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2026NATRNature's Sunshine Products Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B-) ➝ Hold (C+)5/26/2026NATRNature's Sunshine Products Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B) ➝ Buy (B-)5/18/2026FBIOFortress Biotech CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/14/2026OVIDOvid Therapeutics Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.005/11/2026NATRNature's Sunshine Products Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B-) ➝ Buy (B)5/11/2026NATRNature's Sunshine Products DA DavidsonSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$33.005/8/2026NATRNature's Sunshine Products Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$37.004/21/2026OVIDOvid Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026SPROSpero Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026OVIDOvid Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$7.004/9/2026OVIDOvid Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$2.00 ➝ $4.00(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFBIOFortress Biotech$66.16M1.39N/AN/A$2.00 per share1.39MEIPMEI PharmaN/AN/A$6.25 per share0.51$4.96 per shareN/ANATRNature's Sunshine Products$480.14M0.75$2.19 per share9.38$9.23 per share2.22OVIDOvid Therapeutics$7.25M59.21N/AN/A$1.00 per share2.30SPROSpero Therapeutics$66.80M2.47$0.16 per share17.75$1.05 per share2.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFBIOFortress Biotech$6.82M$3.170.871.83N/A193.12%109.66%45.56%8/13/2026 (Estimated)MEIPMEI Pharma$17.78M-$4.75N/AN/AN/AN/A-77.00%-64.79%N/ANATRNature's Sunshine Products$19.52M$1.1018.65N/AN/A4.06%14.67%9.27%7/30/2026 (Estimated)OVIDOvid Therapeutics-$17.41M-$0.29N/AN/AN/A-240.11%-22.51%-18.67%8/12/2026 (Estimated)SPROSpero Therapeutics$8.57M$0.2411.88N/AN/A24.90%35.58%24.95%8/11/2026 (Estimated)Latest FBIO, NATR, MEIP, SPRO, and OVID EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026FBIOFortress Biotech-$0.22$2.82+$3.04$2.82$16.34 million$16.04 million5/13/2026Q1 2026SPROSpero Therapeutics-$0.18-$0.13+$0.05-$0.13$0.26 million$0.26 million5/12/2026Q1 2026OVIDOvid Therapeutics-$0.12-$0.12N/A-$0.12$0.06 millionN/A5/7/2026Q1 2026NATRNature's Sunshine Products$0.2050$0.30+$0.0950$0.29$122.15 million$122.89 million3/31/2026Q4 2025FBIOFortress Biotech$0.11-$0.21-$0.32-$0.21$26.17 million$16.08 million3/26/2026Q4 2025SPROSpero Therapeutics-$0.20$0.53+$0.73$0.53$26.00 million$41.30 million3/18/2026Q4 2025OVIDOvid Therapeutics-$0.10$0.06+$0.16$0.06$0.06 million$0.72 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthFBIOFortress BiotechN/AN/AN/AN/AN/AMEIPMEI PharmaN/AN/AN/AN/AN/ANATRNature's Sunshine ProductsN/AN/AN/AN/AN/AOVIDOvid TherapeuticsN/AN/AN/AN/AN/ASPROSpero TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFBIOFortress Biotech0.182.862.77MEIPMEI PharmaN/A16.7816.78NATRNature's Sunshine ProductsN/A2.501.56OVIDOvid Therapeutics0.0610.1710.17SPROSpero TherapeuticsN/A10.5010.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFBIOFortress Biotech96.51%MEIPMEI Pharma52.38%NATRNature's Sunshine Products79.40%OVIDOvid Therapeutics72.24%SPROSpero Therapeutics25.60%Insider OwnershipCompanyInsider OwnershipFBIOFortress Biotech28.50%MEIPMEI Pharma3.12%NATRNature's Sunshine Products3.10%OVIDOvid Therapeutics7.00%SPROSpero Therapeutics2.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFBIOFortress Biotech17033.22 million23.75 millionOptionableMEIPMEI Pharma10032.84 million31.81 millionOptionableNATRNature's Sunshine Products85017.58 million17.04 millionOptionableOVIDOvid Therapeutics60186.64 million173.58 millionOptionableSPROSpero Therapeutics15057.90 million56.22 millionOptionableFBIO, NATR, MEIP, SPRO, and OVID HeadlinesRecent News About These CompaniesSpero Therapeutics: Approval Upside, Commercial Friction (Initiating Hold)June 10 at 7:26 PM | seekingalpha.comSpero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business UpdateMay 13, 2026 | globenewswire.comEsther Rajavelu Sells 25,240 Shares of Spero Therapeutics (NASDAQ:SPRO) StockMay 7, 2026 | insidertrades.comSpero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026May 5, 2026 | globenewswire.comSpero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business UpdateMarch 26, 2026 | globenewswire.comSpero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026March 18, 2026 | globenewswire.comSpero Therapeutics: Tebipenem's FDA Path Supports A Speculative BuyFebruary 11, 2026 | seekingalpha.comSpero Therapeutics (NASDAQ:SPRO) Insider Sells $207,484.12 in StockFebruary 10, 2026 | insidertrades.comInsider Selling: Spero Therapeutics (NASDAQ:SPRO) Insider Sells 18,442 Shares of StockFebruary 6, 2026 | insidertrades.comWhy Spero Therapeutics, Inc.’s (SPRO) Stock Is Up 7.48%February 4, 2026 | aaii.comAFormer Spero execs fined by SEC over antibiotic efficacy claimsJanuary 20, 2026 | fiercebiotech.comFSpero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including PyelonephritisDecember 19, 2025 | globenewswire.comIs Spero Therapeutics (NASDAQ:SPRO) In A Good Position To Deliver On Growth Plans?December 15, 2025 | finance.yahoo.comSpero Therapeutics (SPRO) price target decreased by 20.00% to 4.08December 6, 2025 | msn.comSpero Therapeutics announces inducement grant under Nasdaq listing ruleNovember 29, 2025 | msn.comSpero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)November 28, 2025 | globenewswire.comSpero Therapeutics Focuses on Tebipenem HBr ProgramNovember 14, 2025 | msn.comSpero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business UpdateNovember 13, 2025 | globenewswire.comSpero Therapeutics (NASDAQ:SPRO) Insider Sells $95,439.90 in StockNovember 13, 2025 | insidertrades.comInsights Ahead: Spero Therapeutics's Quarterly EarningsNovember 13, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20263 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPOBy Ryan Hasson | May 20, 2026Datadog Soars, Dynatrace Slumps: Gap Widens in AI Agent StocksBy Leo Miller | May 18, 2026FBIO, NATR, MEIP, SPRO, and OVID Company DescriptionsFortress Biotech NASDAQ:FBIO$2.77 +0.01 (+0.36%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$2.74 -0.03 (-1.08%) As of 06/12/2026 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.MEI Pharma NASDAQ:MEIPMEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.Nature's Sunshine Products NASDAQ:NATR$20.51 +0.11 (+0.54%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$20.50 -0.01 (-0.05%) As of 06/12/2026 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is headquartered in Lehi, Utah.Ovid Therapeutics NASDAQ:OVID$2.30 +0.09 (+4.07%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$2.28 -0.02 (-0.70%) As of 06/12/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.Spero Therapeutics NASDAQ:SPRO$2.85 +0.15 (+5.56%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$2.84 -0.02 (-0.53%) As of 06/12/2026 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears This Energy Stock Has Quietly Soared 130% in a Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
